Originally from South Eastern France, Chris obtained his Ph.D. in 2010 under the guidance of Professor Jean Rodriguez and Prof. Thierry Constantieux at the Aix-Marseille Université. After three years of postdoctoral studies working with Prof. Bill Roush at Scripps Florida, Chris joined Pfizer in Groton, CT (USA) as a medicinal chemist where he advanced several projects to clinical candidate nomination. In 2017, he switched gear and joined the Chemical Research and Development department where he contributed to the design of chemical processes for Pfizer APIs and led multiple early programs through the clinic. In 2020, he was responsible for the initial clinical deliveries of PF-07321332, Pfizer COVID-19 oral inhibitor, and helped advance the drug candidate at lightspeed throughout 2021. Chris is co-author on more than 25 peer-reviewed publications, reviews, book chapters and patents, and received the Young Investigator Award from the American Chemical Society in 2021.